Our favorite investable areas in brain health with PsyMed Ventures
Greg and Matias chat with Brooks about the evolution of PsyMed Ventures’ investment strategy: a human-first approach to neurotech, novel therapeutics, consumer health, and precision neuroscience
External link. We are not responsible for the content.
Read more ↗More From PsyMed Ventures
Digital Addiction: The Investment Landscape + What Wins Now
The first thing many of us touch in the morning is a screen. Checking notifications quickly turns into a scroll, the ...
How Gilgamesh Landed a $1.2B AbbVie Deal in Psychedelics
Jonathan Sporn (CEO + Founder of Gilgamesh Pharma) joins for a deep dive into next-gen psychedelic medicines, why dur...
The Future of Whole Brain Emulation
Whole brain emulation without the sci-fi, by PsyMed’s Danny Carbonero
Latest News
Where Does the World Go to Dance? Probs These EDM Festivals
A global guide to the festivals worth planning for. [...] Read More... The post Where Does the World Go to Dance? Pro...
Inclius Alvarious’s Place Within Indigenous Society
A look at Sonoran Desert toad medicine through the lens of indigenous sovereignty, ecological strain, and the debate ...
Can you kill a bad trip?: 5 Questions for emergency physician Gregory Yates
Yates discusses experimental attempts to end a psychedelic trip early.
Psychedelic Faeries Take on Prohibition and Authoritarianism
Plus psychedelics and telepathy, ego death for the rich, and our brain on Chat GPT [...] Read More... The post Psyche...
Introduction to Trip Sitting
The Art and Science of Holding Psychedelic Space
Heartbreak is a Bad Trip
Oli Genn-Bash describes how the aftermath of a sudden breakup felt like a prolonged ‘bad trip’, as well as the potent...